# Case Report: Endoscopic-guided electrochemotherapy combined with metronomic chemotherapy for the treatment of nasal tumors in dogs

**Authors:** Giulia Maggi, Alfredo Dentini, Giuseppe Giovannini, Chiara Paloni, Davide De Lorenzi, Maria Chiara Marchesi

PMC · DOI: 10.3389/fvets.2026.1756592 · Frontiers in Veterinary Science · 2026-02-11

## TL;DR

This case report describes a new treatment combining electrochemotherapy and metronomic chemotherapy to successfully reduce nasal tumors in two dogs.

## Contribution

The study introduces endoscopic-guided electrochemotherapy combined with metronomic chemotherapy for canine nasal tumors.

## Key findings

- Both dogs showed reduced tumor size and resolution of clinical signs after the third ECT session.
- Follow-up CT and endoscopy confirmed significant volumetric tumor reduction and improved nasal airflow.
- The treatment was associated with only mild intraoperative bleeding.

## Abstract

Electrochemotherapy is a local anticancer treatment used for selected cutaneous tumors, but its application in veterinary medicine for nasal neoplasms is only rarely reported. Two dogs with endonasal tumors, ineligible for radiotherapy, underwent endoscopic-guided electrochemotherapy (ECT). Each cycle included three sessions spaced 3 weeks apart. Under general anesthesia and endoscopic guidance, bleomycin (20,000 IU/m2) was administered intravenously, followed by bipolar electroporation via a new single needle electrode. Palliative metronomic chemotherapy (piroxicam, thalidomide, and cyclophosphamide) was also administered as an adjuvant to the local treatment. Both dogs showed reduced tumor size and resolution of clinical signs after the third ECT session. Only mild intraoperative bleeding was observed. Follow-up CT and endoscopy confirmed significant volumetric tumor reduction and improved nasal airflow. Endoscopic-guided ECT combined with metronomic chemotherapy appears to be a promising palliative approach for canine endonasal tumors, providing tumor cytoreduction and improvement of clinical signs. Further studies with larger sample sizes and longer follow-up periods are needed to confirm the safety and efficacy of this approach, either alone or in combination with other surgical or medical treatments.

## Linked entities

- **Chemicals:** bleomycin (PubChem CID 5360373), piroxicam (PubChem CID 54676228), thalidomide (PubChem CID 5426), cyclophosphamide (PubChem CID 2907)

## Full-text entities

- **Diseases:** metastasis (MESH:D009362), bone (MESH:D001847), osteolysis of (MESH:D010014), cytotoxic (MESH:D064420), infection (MESH:D007239), bacterial (MESH:D001424), abnormal respiratory sounds (MESH:D012135), nasal carcinoma (MESH:D009669), fungal (MESH:D009181), pain (MESH:D010146), inflammation (MESH:D007249), rarefaction of the (MESH:D000073436), edema (MESH:D004487), undifferentiated nasal carcinoma (MESH:D002277), Blood loss (MESH:D016063), atrophic (MESH:D020966), atrophy (MESH:D001284), AD (MESH:D000544), Tumors (MESH:D009369), epistaxis (MESH:D004844), hyperemia (MESH:D006940), bleeding (MESH:D006470), ischemia (MESH:D007511), respiratory distress (MESH:D012128)
- **Chemicals:** cisplatin (MESH:D002945), prednisolone (MESH:D011239), lipid (MESH:D008055), TC (MESH:D013667), adrenaline (MESH:D004837), chlorambucil (MESH:D002699), piroxicam (MESH:D010894), water (MESH:D014867), tranexamic acid (MESH:D014148), cyclophosphamide (MESH:D003520), Bleomycin (MESH:D001761), thalidomide (MESH:D013792)
- **Species:** Homo sapiens (human, species) [taxon 9606], Canis lupus familiaris (dog, subspecies) [taxon 9615]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12932214/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12932214/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12932214/full.md

---
Source: https://tomesphere.com/paper/PMC12932214